Filing Details

Accession Number:
0001104659-11-006516
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-02-10 12:00:00
Reporting Period:
2011-02-08
Filing Date:
2011-02-10
Accepted Time:
2011-02-10 20:35:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1396814 Pacira Pharmaceuticals Inc. PCRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1232258 Ltd Cayman Bioventures Hbm Centennial Towers, 3Rd Floor
2454 West Bay Road
Grand Cayman, Cayman Islands
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-02-08 1,487,680 $0.00 1,580,660 No 4 C Direct
Common Stock Acquisiton 2011-02-08 1,021,223 $13.44 2,601,883 No 4 C Direct
Common Stock Acquisiton 2011-02-08 267,857 $7.00 2,869,740 No 4 P Direct
Common Stock Acquisiton 2011-02-08 267,857 $7.00 3,137,597 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Stock Disposition 2011-02-08 1,487,680 $0.00 1,487,680 $0.00
Common Stock Convertible Promissory Note Disposition 2011-02-08 1,021,223 $0.00 1,021,223 $13.44
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Represents shares of Common Stock acquired upon the automatic conversion of Series A convertible preferred stock upon the closing of the Issuer's initial public offering of Common Stock.
  2. The Series A convertible preferred stock did not have an expiration date. The Series A convertible preferred stock automatically converted into shares of Common Stock at an effective conversion ratio of one-to-one upon the closing of the Issuer's initial public offering of Common Stock.
  3. Represents shares of Common Stock acquired upon the automatic conversion of all principal and accrued interest due on these convertible promissory notes upon the closing of the Issuer's initial public offering of Common Stock at an effective conversion price of approximately $13.44.
  4. These shares of Common Stock were acquired upon conversion of a convertible promissory note exempt from the definition of a derivative security because the conversion price of such securities did not become fixed until their automatic conversion at the time of closing of the Issuer's initial public offering of Common Stock.
  5. Represents shares of Common Stock acquired upon the conversion of a convertible promissory note issued in December 2010. The outstanding principal amount and accrued but unpaid interest therein was automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock at an effective conversion price of $7.00 which represents the initial public offering price per share of the Common Stock sold by the issuer..